TY - JOUR
T1 - KIF1A variants are a frequent cause of autosomal dominant hereditary spastic paraplegia
AU - Pennings, Maartje
AU - Schouten, Meyke I.
AU - van Gaalen, Judith
AU - Meijer, Rowdy P.P.
AU - de Bot, Susanne T.
AU - Kriek, Marjolein
AU - Saris, Christiaan G.J.
AU - van den Berg, Leonard H.
AU - van Es, Michael A.
AU - Zuidgeest, Dick M.H.
AU - Elting, Mariet W.
AU - van de Kamp, Jiddeke M.
AU - van Spaendonck-Zwarts, Karin Y.
AU - Die-Smulders, Christine de
AU - Brilstra, Eva H.
AU - Verschuuren, Corien C.
AU - de Vries, Bert B.A.
AU - Bruijn, Jacques
AU - Sofou, Kalliopi
AU - Duijkers, Floor A.
AU - Jaeger, B.
AU - Schieving, Jolanda H.
AU - van de Warrenburg, Bart P.
AU - Kamsteeg, Erik Jan
N1 - Funding Information:
Funding BPW is supported by research grants from Radboud university medical centre, ZonMW, Bioblast Pharma and Hersenstichting. EHB received funding for research on epilepsy genetics from the Stichting Panta Rhei, the Dutch Epilepsy Foundation, and the COFRA foundation. MK funding from the European Community’s Horizon 2020 Programme under grant agreement No.668353 (U-PGx). MAE receives funding from the Netherlands Organization for Health Research and Development (Veni scheme), The Thierry Latran Foundation, the ALS Foundation Netherlands and JPND, has consulted for Biogen and has received travel grants from Shire (formerly Baxalta). LHB reports grants from Netherlands ALS Foundation, grants from Prinses Beatrix Spierfonds, grants from Netherlands, Organization for Health Research and Development (Vici scheme), and personal fees from Baxter for scientific advisory board and travel grant, and personal fees from Scientific Advisory Board, Biogen Idec, outside the submitted work. No other authors have received any funding from any institution, including personal relationships, interests, grants, employment, affiliations, patents, inventions, honoraria, consultancies, royalties, stock options/ownership, or expert testimony for the last 12 months.
Publisher Copyright:
© 2019, The Author(s).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/1
Y1 - 2020/1
N2 - Variants in the KIF1A gene can cause autosomal recessive spastic paraplegia 30, autosomal recessive hereditary sensory neuropathy, or autosomal (de novo) dominant mental retardation type 9. More recently, variants in KIF1A have also been described in a few cases with autosomal dominant spastic paraplegia. Here, we describe 20 KIF1A variants in 24 patients from a clinical exome sequencing cohort of 347 individuals with a mostly 'pure' spastic paraplegia. In these patients, spastic paraplegia was slowly progressive and mostly pure, but with a highly variable disease onset (0-57 years). Segregation analyses showed a de novo occurrence in seven cases, and a dominant inheritance pattern in 11 families. The motor domain of KIF1A is a hotspot for disease causing variants in autosomal dominant spastic paraplegia, similar to mental retardation type 9 and recessive spastic paraplegia type 30. However, unlike these allelic disorders, dominant spastic paraplegia was also caused by loss-of-function variants outside this domain in six families. Finally, three missense variants were outside the motor domain and need further characterization. In conclusion, KIF1A variants are a frequent cause of autosomal dominant spastic paraplegia in our cohort (6-7%). The identification of KIF1A loss-of-function variants suggests haploinsufficiency as a possible mechanism in autosomal dominant spastic paraplegia.
AB - Variants in the KIF1A gene can cause autosomal recessive spastic paraplegia 30, autosomal recessive hereditary sensory neuropathy, or autosomal (de novo) dominant mental retardation type 9. More recently, variants in KIF1A have also been described in a few cases with autosomal dominant spastic paraplegia. Here, we describe 20 KIF1A variants in 24 patients from a clinical exome sequencing cohort of 347 individuals with a mostly 'pure' spastic paraplegia. In these patients, spastic paraplegia was slowly progressive and mostly pure, but with a highly variable disease onset (0-57 years). Segregation analyses showed a de novo occurrence in seven cases, and a dominant inheritance pattern in 11 families. The motor domain of KIF1A is a hotspot for disease causing variants in autosomal dominant spastic paraplegia, similar to mental retardation type 9 and recessive spastic paraplegia type 30. However, unlike these allelic disorders, dominant spastic paraplegia was also caused by loss-of-function variants outside this domain in six families. Finally, three missense variants were outside the motor domain and need further characterization. In conclusion, KIF1A variants are a frequent cause of autosomal dominant spastic paraplegia in our cohort (6-7%). The identification of KIF1A loss-of-function variants suggests haploinsufficiency as a possible mechanism in autosomal dominant spastic paraplegia.
UR - http://www.scopus.com/inward/record.url?scp=85073775799&partnerID=8YFLogxK
U2 - 10.1038/s41431-019-0497-z
DO - 10.1038/s41431-019-0497-z
M3 - Article
C2 - 31488895
SN - 1018-4813
VL - 28
SP - 40
EP - 49
JO - European Journal of Human Genetics
JF - European Journal of Human Genetics
IS - 1
ER -